Summary:
A Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing
Generic to Reference Paliperidone Palmitate Extended-Release Injectable
Suspension (156 mg/1.0 mL) in Patients with Schizophrenia or
Schizoaffective Disorder
Qualified Participants Must:
• Males and females 18 to 64 years of age
•
Diagnosis of schizophrenia or schizoaffective disorder
Qualified Participants May Receive:
Compensation for time and travel